Regenxbio Inc. (RGNX) intrinsic value & 10-year financials
Regenxbio Inc. (RGNX) has a Graham intrinsic value of $96.66 per share. At $6.93 on Oct 17, 2026, the stock trades 93% below that value. Over the last 10 fiscal years revenue grew 49.4% a year to $170.4M, with an average return on invested capital of -35.3%.
- Graham intrinsic value
- $96.66
- Share price (Oct 17, 2026)
- $6.93
- Price vs Graham value
- 93% below
- Market cap
- $357.1M
- Revenue (FY2025)
- $170.4M
- Revenue growth (10-yr CAGR)
- 49.4%
- ROIC (10-yr avg)
- -35.3%
- Free cash flow (FY2025)
- -$126.4M
RGNX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $170.4M | -$193.9M | -$3.76 | -$126.4M | -94.6% | -78.7% |
| FY2024 | $83.3M | -$227.1M | -$4.59 | -$175.6M | -280.0% | -73.4% |
| FY2023 | $90.2M | -$263.5M | -$6.02 | -$228.4M | -297.1% | -61.8% |
| FY2022 | $112.7M | -$280.3M | -$6.50 | -$238.2M | -233.2% | -51.9% |
| FY2021 | $470.3M | $127.8M | $2.91 | $134.7M | 34.0% | 47.2% |
| FY2020 | $154.6M | -$111.2M | -$2.98 | -$80.9M | -77.1% | -47.8% |
| FY2019 | $35.2M | -$94.7M | -$2.58 | -$119.4M | -422.9% | -34.9% |
| FY2018 | $218.5M | $99.9M | $2.73 | $91.4M | 40.3% | 19.3% |
| FY2017 | $10.4M | -$73.2M | -$2.45 | -$65.2M | -730.2% | — |
| FY2016 | $4.6M | -$63.0M | -$2.38 | -$56.7M | -1423.8% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
REGENXBIO Inc. is a consistent compounder, expanding top-line revenue at 49.4% annually over the past decade.
REGENXBIO Inc. has historically struggled to out-earn its cost of capital, averaging just -35.3% ROIC.
REGENXBIO Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, REGENXBIO Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $96.66 per share.